Paper16916645
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation.
Machida YJ and 6 others. Mol Cell, 2006. Cited by 238 papers, by iCite.
Cite this record
ConductScience Library. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Papers, record 16916645. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16916645
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fanconi Anemia | Major topic |
| Homeostasis | Major topic |
| Ubiquitin-Conjugating Enzymes | Major topic |
| Chromosome Aberrations | |
| Fanconi Anemia Complementation Group D2 Protein | |
| Fanconi Anemia Complementation Group L Protein | |
| Humans | |
| Mitomycin | |
| Molecular Sequence Data | |
| Protein Binding | |
| Tumor Cells, Cultured | |
| Ubiquitin |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA060499 | NCI NIH HHS | United States | R01CA060499 | PubMed and NIH | NIH RePORTER |
| R01 CA60499 | NCI NIH HHS | United States | R01CA060499 | PubMed and NIH | NIH RePORTER |
| R01 HL063776 | NHLBI NIH HHS | United States | R01HL063776 | PubMed and NIH | NIH RePORTER |
Cited by172
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 238 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42937821 | Ubiquitin Chloromethylketone Probe Enables Activity-Based Protein Profiling of E2 Ubiquitin Conjugating Enzymes. | J Am Chem Soc | 2026 | https://conductscience.org/library/papers/42937821 | PubMed |
| 42846171 | Atypical Presentation of UBE2T-Related Fanconi Anemia With Immune-Mediated Thrombocytopenia and Hematopoietic Somatic Mosaicism: A Case Report. | EJHaem | 2026 | https://conductscience.org/library/papers/42846171 | PubMed |
| 42292533 | Critical Biological Functions and Clinical Implications of Epigenetic-Related Candidate Biomarkers in Chronic Obstructive Pulmonary Disease: Integrated Machine Learning Screening and Basic Experimental Validation. | Int J Chron Obstruct Pulmon Dis | 2026 | https://conductscience.org/library/papers/42292533 | PubMed |
| 42152107 | DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42152107 | PubMed |
| 42074182 | Intron Retention as a Homeostatic State Variable for Drug Response and Recovery: Lessons from Depression for Broader Applications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074182 | PubMed |
| 41751958 | FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751958 | PubMed |
| 41673685 | Identification of UBE2T as a novel diagnostic biomarker of psoriasis and proliferating UBE2T+ Keratinocyte in psoriasis. | J Transl Med | 2026 | https://conductscience.org/library/papers/41673685 | PubMed |
| 40710415 | Computational and Imaging Approaches for Precision Characterization of Bone, Cartilage, and Synovial Biomolecules. | J Pers Med | 2025 | https://conductscience.org/library/papers/40710415 | PubMed |
| 40274197 | USP1 inhibition: A journey from target discovery to clinical translation. | Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40274197 | PubMed |
| 40259951 | Analysis of Ubiquitin-Conjugating Enzyme E2T (UBE2T) Protein Levels in the Bone Marrow Biopsy Specimens of Patients With Multiple Myeloma. | Cureus | 2025 | https://conductscience.org/library/papers/40259951 | PubMed |
| 39915000 | UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/39915000 | PubMed |
| 39851497 | Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities. | Cells | 2025 | https://conductscience.org/library/papers/39851497 | PubMed |
| 39791716 | Unraveling the Role of Ubiquitin-Conjugating Enzyme UBE2T in Tumorigenesis: A Comprehensive Review. | Cells | 2024 | https://conductscience.org/library/papers/39791716 | PubMed |
| 39289660 | UBE2T promotes stage I lung adenocarcinoma progression through PBX1 ubiquitination and PBX1/RORA regulation. | BMC Cancer | 2024 | https://conductscience.org/library/papers/39289660 | PubMed |
| 38846492 | Research progress on the fanconi anemia signaling pathway in non-obstructive azoospermia. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38846492 | PubMed |
| 38626770 | Global, site-resolved analysis of ubiquitylation occupancy and turnover rate reveals systems properties. | Cell | 2024 | https://conductscience.org/library/papers/38626770 | PubMed |
| 38584528 | Knockdown of Ubiquitin-Conjugating Enzyme E2 T Abolishes the Progression of Head and Neck Squamous Cell Carcinoma by Inhibiting NF-Κb Signaling and inducing Ferroptosis. | Curr Protein Pept Sci | 2024 | https://conductscience.org/library/papers/38584528 | PubMed |
| 38358126 | Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening. | Protein Sci | 2024 | https://conductscience.org/library/papers/38358126 | PubMed |
| 38332367 | Structural mechanisms of autoinhibition and substrate recognition by the ubiquitin ligase HACE1. | Nat Struct Mol Biol | 2024 | https://conductscience.org/library/papers/38332367 | PubMed |
| 37923882 | DNA Damage Responses, the Trump Card of Stem Cells in the Survival Game. | Adv Exp Med Biol | 2024 | https://conductscience.org/library/papers/37923882 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FANCD2 | 2177 | Swiss-Prot's references | https://conductscience.org/library/genes/2177 | NCBI Gene |
| FANCL | 55120 | Swiss-Prot's references | https://conductscience.org/library/genes/55120 | NCBI Gene |
| UBE2T | 29089 | Swiss-Prot's references | https://conductscience.org/library/genes/29089 | NCBI Gene |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| RefSeq | NM_014176 |
Source RefSeq
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16916645
GET https://conductscience.org/api/papers/v1/16916645/cited_by?page=2